Conmed (CNMD)
Conmed on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as electromedical & electrotherapeutic apparatus.
2.0M
Short interest
settlement 2026-09-30
5.2
Days to cover
-2.1 days vs prior
41.7%
Short share of volume
2026-10-12
3,268
Fails to deliver
settlement 2026-09-10
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-12.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in CNMD is 1,955,193 shares, down 309,016 shares over the last month. Over the last 48 readings it ranged from 1,955,193 shares (30 September 2026) to 2,804,602 shares (14 March 2025). The latest reading sits at the bottom of that range. At the reported average volume of 374K shares a day that is 5.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cnmd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 1,955,193 | -8.5% | 373,796 | 5.23 |
| 2026-09-15 | 2,137,300 | -5.6% | 292,435 | 7.31 |
| 2026-08-31 | 2,264,209 | -2.4% | 315,282 | 7.18 |
| 2026-08-14 | 2,319,480 | +3.8% | 463,121 | 5.01 |
| 2026-07-31 | 2,234,640 | -4.1% | 644,227 | 3.47 |
| 2026-07-15 | 2,329,178 | -8.0% | 943,826 | 2.47 |
| 2026-06-30 | 2,532,742 | +17.6% | 712,370 | 3.56 |
| 2026-06-15 | 2,153,699 | -8.1% | 550,737 | 3.91 |
| 2026-05-29 | 2,342,164 | +2.2% | 433,890 | 5.40 |
| 2026-05-15 | 2,292,273 | -7.5% | 434,690 | 5.27 |
| 2026-04-30 | 2,479,470 | +7.3% | 454,401 | 5.46 |
| 2026-04-15 | 2,310,061 | +3.6% | 388,868 | 5.94 |
| 2026-03-31 | 2,230,689 | -1.0% | 432,831 | 5.15 |
| 2026-03-13 | 2,253,412 | -6.7% | 424,182 | 5.31 |
| 2026-02-27 | 2,415,721 | +17.7% | 531,083 | 4.55 |
| 2026-02-13 | 2,052,417 | -9.6% | 552,583 | 3.71 |
| 2026-01-30 | 2,271,084 | -2.3% | 734,015 | 3.09 |
| 2026-01-15 | 2,324,643 | -1.4% | 637,339 | 3.65 |
| 2025-12-31 | 2,357,218 | -0.2% | 516,982 | 4.56 |
| 2025-12-15 | 2,362,201 | +1.8% | 688,671 | 3.43 |
| 2025-11-28 | 2,321,626 | +3.2% | 566,255 | 4.10 |
| 2025-11-14 | 2,249,552 | -2.0% | 546,090 | 4.12 |
| 2025-10-31 | 2,295,080 | +9.4% | 379,483 | 6.05 |
| 2025-10-15 | 2,097,899 | +1.3% | 318,036 | 6.60 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 12 October 2026, the short share of CNMD volume is 41.7%, down 17.7 points over the last five sessions. Over the last 30 readings it ranged from 34.6% (9 October 2026) to 79.7% (24 September 2026). The latest reading is 16.6 points below the 30-session average of 58.2%, on 171K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-12 | 71K | 171K | 41.7% | 0 |
| 2026-10-09 | 48K | 140K | 34.6% | 0 |
| 2026-10-08 | 67K | 108K | 62.1% | 0 |
| 2026-10-07 | 66K | 118K | 55.6% | 0 |
| 2026-10-06 | 76K | 146K | 51.8% | 0 |
| 2026-10-05 | 58K | 98K | 59.3% | 0 |
| 2026-10-02 | 61K | 99K | 61.6% | 0 |
| 2026-10-01 | 43K | 72K | 59.2% | 0 |
| 2026-09-30 | 55K | 98K | 56.1% | 0 |
| 2026-09-29 | 46K | 63K | 72.3% | 0 |
| 2026-09-28 | 76K | 126K | 60.1% | 0 |
| 2026-09-25 | 54K | 98K | 54.6% | 0 |
| 2026-09-24 | 81K | 102K | 79.7% | 0 |
| 2026-09-23 | 110K | 222K | 49.8% | 0 |
| 2026-09-22 | 88K | 147K | 59.9% | 0 |
| 2026-09-21 | 86K | 138K | 62.4% | 0 |
| 2026-09-18 | 66K | 97K | 68.0% | 0 |
| 2026-09-17 | 69K | 130K | 53.2% | 0 |
| 2026-09-16 | 75K | 125K | 59.5% | 0 |
| 2026-09-15 | 95K | 153K | 62.1% | 0 |
| 2026-09-14 | 78K | 137K | 56.6% | 0 |
| 2026-09-11 | 58K | 103K | 56.8% | 0 |
| 2026-09-10 | 57K | 95K | 60.3% | 0 |
| 2026-09-09 | 58K | 93K | 61.8% | 0 |
| 2026-09-08 | 57K | 124K | 45.9% | 0 |
| 2026-09-04 | 50K | 86K | 58.7% | 0 |
| 2026-09-03 | 74K | 101K | 73.3% | 0 |
| 2026-09-02 | 65K | 113K | 57.5% | 0 |
| 2026-09-01 | 48K | 77K | 62.8% | 0 |
| 2026-08-31 | 40K | 80K | 50.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 10 September 2026, the fails-to-deliver balance in CNMD is 3,268 shares, up 2,804 shares over the last settlement date. Over the last 30 readings it ranged from 16 shares (20 March 2026) to 65,189 shares (23 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-10 | 3,268 | $46.93 | $153K |
| 2026-08-31 | 464 | $49.98 | $23K |
| 2026-08-19 | 381 | $49.26 | $19K |
| 2026-08-04 | 225 | $51.86 | $12K |
| 2026-08-03 | 37 | $46.30 | $2K |
| 2026-07-20 | 251 | $43.20 | $11K |
| 2026-07-16 | 96 | $42.79 | $4K |
| 2026-07-14 | 37 | $42.41 | $2K |
| 2026-07-09 | 183 | $33.59 | $6K |
| 2026-07-06 | 563 | $33.83 | $19K |
| 2026-07-01 | 18 | $32.73 | $589 |
| 2026-06-30 | 4,105 | $34.41 | $141K |
| 2026-06-29 | 140 | $35.95 | $5K |
| 2026-06-23 | 65,189 | $32.54 | $2.1M |
| 2026-06-16 | 11,810 | $34.16 | $403K |
| 2026-06-15 | 43,032 | $34.77 | $1.5M |
| 2026-06-12 | 43,455 | $34.41 | $1.5M |
| 2026-06-09 | 7,125 | $34.49 | $246K |
| 2026-05-13 | 4,650 | $35.97 | $167K |
| 2026-05-06 | 97 | $36.64 | $4K |
| 2026-05-05 | 237 | $35.88 | $9K |
| 2026-05-01 | 30 | $36.66 | $1K |
| 2026-04-28 | 693 | $37.87 | $26K |
| 2026-04-27 | 138 | $38.34 | $5K |
| 2026-04-24 | 268 | $37.50 | $10K |
| 2026-04-22 | 800 | $38.35 | $31K |
| 2026-04-21 | 4,011 | $39.68 | $159K |
| 2026-04-17 | 3,937 | $37.91 | $149K |
| 2026-03-23 | 92 | $35.94 | $3K |
| 2026-03-20 | 16 | $36.80 | $589 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for CNMD in the last 90 days. The most recent filings are listed below. Latest filing: Kelderman Kim (Director) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Kelderman Kim | Director | Option exercise | 500 | $0.00 | $0 | 500 |
| 2026-06-02 | Council LaVerne H | Director | Option exercise | 668 | $0.00 | $0 | 5K |
| 2026-06-02 | Farkas Charles | Director | Option exercise | 668 | $0.00 | $0 | 16K |
| 2026-06-02 | Kaye Mark | Director | Option exercise | 668 | $0.00 | $0 | 820 |
| 2026-06-02 | Schwarzentraub Barbara J | Director | Option exercise | 668 | $0.00 | $0 | 5K |
| 2026-06-02 | Bronson David M. | Director | Option exercise | 668 | $0.00 | $0 | 18K |
| 2026-03-06 | Lalomia Brent | Executive VP RA, QA | Tax withholding | 26 | $39.90 | $1K | 915 |
| 2026-03-06 | Lalomia Brent | Executive VP RA, QA | Option exercise | 75 | $0.00 | $0 | 941 |
| 2026-02-24 | Kaye Mark | Director | Option exercise | 152 | $0.00 | $0 | 152 |
| 2025-11-21 | Glaze Richard | Chief Information Officer | Sell | 257 | $41.21 | $11K | 0 |
| 2025-11-20 | Glaze Richard | Chief Information Officer | Tax withholding | 118 | $40.63 | $5K | 257 |
| 2025-11-20 | Glaze Richard | Chief Information Officer | Option exercise | 375 | $0.00 | $0 | 375 |
| 2025-11-06 | Garner Todd W | Executive Vice President & CFO | Sell | 4K | $43.00 | $151K | 2K |
| 2025-11-04 | Foust Hollie K | General Counsel & Corp Sec | Tax withholding | 1K | $45.71 | $51K | 3K |
| 2025-11-04 | Foust Hollie K | General Counsel & Corp Sec | Option exercise | 4K | $0.00 | $0 | 4K |
| 2025-10-31 | Garner Todd W | Executive Vice President & CFO | Tax withholding | 2K | $44.00 | $95K | 5K |
| 2025-10-31 | Garner Todd W | Executive Vice President & CFO | Option exercise | 8K | $0.00 | $0 | 8K |
| 2025-09-12 | Farkas Charles | Director | Sell | 897 | $53.51 | $48K | 15K |
| 2025-09-12 | Farkas Charles | Director | Sell | 1K | $53.53 | $59K | 16K |
| 2025-08-07 | Garner Todd W | Executive Vice President & CFO | Sell | 598 | $52.45 | $31K | 0 |
| 2025-06-03 | Aronson Martha Goldberg | Director | Option exercise | 479 | $0.00 | $0 | 12K |
| 2025-06-03 | Bronson David M. | Director | Option exercise | 479 | $0.00 | $0 | 17K |
| 2025-06-03 | Council LaVerne H | Director | Option exercise | 479 | $0.00 | $0 | 4K |
| 2025-06-03 | Farkas Charles | Director | Option exercise | 479 | $0.00 | $0 | 17K |
| 2025-06-03 | Concannon Brian | Director | Option exercise | 479 | $0.00 | $0 | 10K |
| 2025-06-03 | Schwarzentraub Barbara J | Director | Option exercise | 479 | $0.00 | $0 | 4K |
| 2025-05-29 | Farkas Charles | Director | Tax withholding | 966 | $57.69 | $56K | 16K |
| 2025-05-29 | Farkas Charles | Director | Option exercise | 1K | $55.70 | $56K | 17K |
| 2025-05-20 | Workman John L | Director | Option exercise | 479 | $59.84 | $29K | 21K |
| 2025-05-05 | Farkas Charles | Director | Sell | 4K | $56.94 | $228K | 16K |
| 2025-03-31 | Garner Todd W | Executive Vice President & CFO | Grant | 371 | $57.37 | $21K | 598 |
| 2025-03-14 | SHAGORY PETER K | EVP, STRAT & CORP DEVT | Tax withholding | 4K | $58.83 | $254K | 4K |
| 2025-03-14 | SHAGORY PETER K | EVP, STRAT & CORP DEVT | Option exercise | 5K | $55.42 | $249K | 8K |
| 2025-03-07 | Lalomia Brent | Vice President QA and RA | Option exercise | 75 | $0.00 | $0 | 1K |
| 2025-03-07 | Lalomia Brent | Vice President QA and RA | Tax withholding | 26 | $62.74 | $2K | 1K |
| 2025-02-11 | Glaze Richard | Chief Information Officer | Sell | 257 | $65.35 | $17K | 0 |
| 2024-11-20 | Glaze Richard | Chief Information Officer | Tax withholding | 118 | $70.69 | $8K | 257 |
| 2024-11-20 | Glaze Richard | Chief Information Officer | Option exercise | 375 | $0.00 | $0 | 375 |
| 2024-11-07 | Hartman Curt R | President and CEO | Tax withholding | 24K | $74.76 | $1.8M | 10K |
| 2024-11-07 | Hartman Curt R | President and CEO | Option exercise | 30K | $51.30 | $1.5M | 34K |
| 2024-09-05 | Farkas Charles | Director | Option exercise | 1K | $39.64 | $40K | 21K |
| 2024-09-05 | Farkas Charles | Director | Tax withholding | 534 | $74.31 | $40K | 20K |
| 2024-08-01 | Clifford Edward A. | VP Global Manufacturing | Option exercise | 500 | $0.00 | $0 | 500 |
| 2024-08-01 | Clifford Edward A. | VP Global Manufacturing | Tax withholding | 122 | $65.34 | $8K | 378 |
| 2024-06-14 | Peters Stanley W III | President AS and AET | Option exercise | 4K | $41.93 | $168K | 4K |
| 2024-06-14 | Peters Stanley W III | President AS and AET | Sell | 4K | $71.82 | $287K | 63 |
| 2024-05-31 | Schwarzentraub Barbara J | Director | Option exercise | 302 | $0.00 | $0 | 4K |
| 2024-05-31 | Council LaVerne H | Director | Option exercise | 302 | $0.00 | $0 | 4K |
| 2024-05-31 | Aronson Martha Goldberg | Director | Option exercise | 302 | $0.00 | $0 | 12K |
| 2024-05-31 | Farkas Charles | Director | Option exercise | 302 | $0.00 | $0 | 20K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for CNMD worth $161K at the prices reported; 0 in the last 90 days worth $0. Latest: Glaze Richard filed on 2025-11-21 to sell 257 shares ($11K) from 2025-11-21.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-11-21 | Glaze RichardOfficer | 257 | $11K | 0.001% | 2025-11-21 | Fidelity Brokerage Services LLC |
| 2025-11-06 | Garner Todd WOfficer | 4K | $151K | 0.011% | 2025-11-06 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of CNMD in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 6.9% of the class (2,120,886 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-29 | 13G | Vanguard Portfolio Managementinvestment adviser | 2.1M | 6.9% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 1.6M | 5.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 14 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-11-13 | 13G/Ano. 3 | Capital Research Global Investorsinvestment adviser | 1.0M | 3.3% | 2025-09-30 |
13F holders
Tracked managers holding CNMD at their latest 13F. JSON6 of the 30 tracked managers held CNMD at their latest 13F, $46.0M in total at quarter-end prices. Two Sigma Investments is the largest at $23.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 729K | $23.9M | 0.02% | -54K |
| AQR Capital Management | 2026-06-30 | 281K | $9.2M | 0.00% | +201K |
| Citadel Advisors | 2026-06-30 | 142K | $4.7M | 0.00% | -105K |
| Millennium Management | 2026-06-30 | 115K | $3.8M | 0.00% | +39K |
| Point72 Asset Management | 2026-06-30 | 70K | $2.3M | 0.00% | -65K |
| D. E. Shaw & Co. | 2026-06-30 | 68K | $2.2M | 0.00% | +20K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Conmed reported revenue of $343.5M, up 0.3% from the same quarter a year earlier, and net income of $23.1M (0.77 diluted EPS). In FY 2025 it generated $170.7M of operating cash flow and spent $24.7M on dividends.
- Equity
- $1.04B
- Total assets
- $2.30B
- Shares outstanding
- 29,951,248
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $343.5M | $23.1M | 6.7% | 0.77 |
| Q3 FY 2025 | 2025-09-30 | $337.9M | $2.9M | 0.8% | 0.09 |
| Q2 FY 2025 | 2025-06-30 | $342.3M | $21.4M | 6.3% | 0.69 |
| Q4 FY 2024derived | 2024-12-31 | $345.9M | $33.8M | 9.8% | n/a |
| Q3 FY 2024 | 2024-09-30 | $316.7M | $49.0M | 15.5% | 1.57 |
| Q2 FY 2024 | 2024-06-30 | $332.1M | $30.0M | 9.0% | 0.96 |
| Q1 FY 2024 | 2024-03-31 | $312.3M | $19.7M | 6.3% | 0.63 |
| Q4 FY 2023derived | 2023-12-31 | $327.0M | $33.1M | 10.1% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.37B | $47.1M | $170.7M | $19.8M | n/a | $24.7M |
| FY 2024 | 2024-12-31 | $1.31B | $132.4M | $167.0M | $13.1M | n/a | $24.7M |
| FY 2023 | 2023-12-31 | $1.24B | $64.5M | $125.3M | $19.0M | n/a | $24.5M |
| FY 2022 | 2022-12-31 | $1.05B | -$80.6M | $33.4M | $21.8M | n/a | $24.0M |
| FY 2021 | 2021-12-31 | $1.01B | $62.5M | $111.8M | $14.9M | n/a | $23.3M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
Conmed in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Conmed (CNMD), SEC CIK 816956, listed on NYSE, classified by the SEC as electromedical & electrotherapeutic apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-12.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-10.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-11-21.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 816956Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as electromedical & electrotherapeutic apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of CNMD is sold short?
What is CNMD's daily short volume?
Does CNMD have fails to deliver?
Are CNMD insiders buying or selling?
Have CNMD insiders filed to sell?
Who owns 5% or more of CNMD?
What did CNMD report last quarter?
Which tracked 13F managers own CNMD?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.